MetaCap

MapLight Therapeutics (MPLT) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MapLight Therapeutics (MPLT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 57.5% versus a loss of 61.0%. MapLight Therapeutics is the larger company by market cap ($330.1 million vs $297.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MPLT-57.54%SPRY-61.00%
+197%+60%-78%
Nov 21, 20251 yearNov 20, 2026
MPLT-64.89%SPRY-66.96%
+142%+32%-79%
Oct 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MPLT versus SPRY key metrics
MetricMPLTSPRY
Share price$5.94$2.96
Market cap$330.12M$297.56M
1-day change-7.48%-11.90%
YTD return-66.18%-74.59%
1-year return-57.54%-61.00%
5-year return—-58.83%
EPS (TTM)$-6.07$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-161.15M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$40.43$13.15
52-week low$5.93$2.44
Distance from 52-week high-85.31%-77.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+340.24%+474.32%
Average volume458.71K1.83M
Shares outstanding52.85M100.53M
Employees133203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MapLight Therapeutics

MPLT stock →

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

MPLT vs SPRY FAQ

Which is bigger, MapLight Therapeutics or ARS Pharmaceuticals?

MapLight Therapeutics (MPLT) is larger, with a market capitalization of $330.12M compared with $297.56M for ARS Pharmaceuticals (SPRY).

Which stock has performed better over the past year, MPLT or SPRY?

MPLT returned -57.54% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are MapLight Therapeutics and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons